AstraZeneca (LON:AZN) received a GBX 4,550 ($63.90) price objective from equities research analysts at UBS Group in a research report issued to clients and investors on Monday, January 8th, www.boersen-zeitung.de reports. The brokerage currently has a “neutral” rating on the biopharmaceutical company’s stock. UBS Group’s price objective would suggest a potential downside of 6.73% from the company’s current price.
AZN has been the topic of several other reports. raised their target price on AstraZeneca from GBX 4,100 ($57.58) to GBX 4,150 ($58.28) and gave the company a “reduce” rating in a report on Monday, October 9th. Jefferies Group lifted their price objective on AstraZeneca from GBX 4,350 ($61.09) to GBX 4,800 ($67.41) and gave the stock a “hold” rating in a report on Monday, September 11th. Deutsche Bank reiterated a “buy” rating and issued a GBX 5,600 ($78.64) price target on shares of AstraZeneca in a report on Wednesday, October 11th. Liberum Capital reiterated a “buy” rating and issued a GBX 4,800 ($67.41) price target on shares of AstraZeneca in a report on Monday, September 11th. Finally, Bryan, Garnier & Co upgraded AstraZeneca to a “buy” rating and boosted their price target for the company from GBX 4,700 ($66.00) to GBX 5,380 ($75.55) in a report on Monday, September 11th. Four analysts have rated the stock with a sell rating, six have given a hold rating and thirteen have issued a buy rating to the company. The stock currently has an average rating of “Hold” and a consensus target price of GBX 5,219 ($73.29).
AstraZeneca (LON AZN) opened at GBX 4,878.50 ($68.51) on Monday. The firm has a market capitalization of $61,990.00 and a PE ratio of 2,476.40. AstraZeneca has a 52 week low of GBX 4,150 ($58.28) and a 52 week high of GBX 5,520 ($77.52).
TRADEMARK VIOLATION NOTICE: This article was first reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this article on another domain, it was copied illegally and reposted in violation of U.S. & international trademark and copyright laws. The correct version of this article can be read at https://www.dispatchtribunal.com/2018/02/01/astrazeneca-azn-given-a-gbx-4550-price-target-by-ubs-group-analysts.html.
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.